Skip to main
ARTV

ARTV Stock Forecast & Price Target

ARTV Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Artiva Biotherapeutics Inc. has a promising outlook driven by the strong enrollment figures in their clinical trials, with over a dozen patients reported in August and over 20 anticipated by November, indicating limited safety concerns. The company's pipeline, including the AlloNK therapy aimed at enhancing antibody-dependent cellular cytotoxicity, holds the potential for significantly improved clinical outcomes, which is reflected in the bullish assumptions around durable remissions. Moreover, there is potential for substantial near-term appreciation based on the modest premium in after-hours trading compared to projected cash values, especially as substantial data sets are expected to emerge in the coming months.

Bears say

Artiva Biotherapeutics's financial outlook is negatively impacted by the uncertainty surrounding its lead candidate, AlloNK, with assumptions suggesting a 10% probability of success (POS) due to potential failures in achieving deep B-cell aplasia or tolerability concerns. This scenario indicates a potential downside of approximately 25% to 40% from the company's Base Case estimates. Furthermore, the risks associated with generating additional successful clinical candidates from its NK cell therapy platform compound the company's challenges, contributing to a dim perspective on future revenue generation.

ARTV has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Artiva Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Artiva Biotherapeutics Inc (ARTV) Forecast

Analysts have given ARTV a Strong Buy based on their latest research and market trends.

According to 3 analysts, ARTV has a Strong Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Artiva Biotherapeutics Inc (ARTV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.